Trial · NCT07495579
Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)
NCT07495579, Phase 2, Not yet recruiting, Asan Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE). Trials, record NCT07495579. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07495579
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)
- NCT number
- NCT07495579
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 146 participants, estimated
- Lead sponsor
- Asan Medical Center
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Lenvatinib, regorafenib
- First posted
- 2026-03-27
- Last updated
- 2026-05-27
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-Free Survival (PFS) in REVIVE-1 | Up to 24 months | Progression-free survival is defined as the time from first dose of study treatment to disease progression according to RECIST v1.1 or death from any cause, whichever occurs first, in the REVIVE-1 cohort. |
| Primary | Overall Survival (OS) in REVIVE-2 | Up to 30 months | Overall survival is defined as the time from first dose of study treatment to death from any cause in the REVIVE-2 cohort. |
| Secondary | Overall Survival (OS) in REVIVE-1 | Up to 24 months | Overall survival is defined as the time from first dose of study treatment to death from any cause in the REVIVE-1 cohort. |
| Secondary | Progression-Free Survival (PFS) in REVIVE-2 | Up to 30 months | Progression-free survival is defined as the time from first dose of study treatment (lenvatinib or regorafenib) to the first documented disease progression according to RECIST v1.1 or death from any cause, whichever occurs first, in the REVIVE-2 cohort. |
| Secondary | Objective Response Rate (ORR) | Up to 24 months | Objective response rate is defined as the proportion of participants who achieve a confirmed complete response or partial response according to RECIST v1.1. in both REVIVE-1 and REVIVE-2 cohorts. |
| Secondary | Incidence of Treatment-Emergent Adverse Events | Up to 30 months | The incidence and severity of treatment-emergent adverse events will be assessed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 in both REVIVE-1 and REVIVE-2 cohorts. |
| Secondary | Time to Liver Function Deterioration in REVIVE-2 | Up to 30 months | Time to liver function deterioration is defined as the time from first dose of study treatment to worsening of liver function, such as progression from Child-Pugh B7 to B8-9 or C, from Child-Pugh B8 to B9 or C, or worsening of albumin-bilirubin (ALBI) grade from 2 to 3. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07495579
GET https://conductscience.org/api/trials/v1/NCT07495579/registered